Olema Pharmaceuticals, Inc. Stock Price, News & Analysis

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women’s cancers, announced the participation of its President and CEO, Sean Bohen, in a panel discussion on “ER+/HER2- Breast Cancer” at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference. This event is scheduled for April 20, 2023, at 2:00 p.m. ET.

Olema's lead product candidate, OP-1250, is an innovative treatment designed as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Currently in a Phase 2 clinical trial, OP-1250 is being assessed as a single agent and in combination with existing therapies for patients with recurrent advanced ER-positive, HER2-negative breast cancer. The FDA has granted it Fast Track designation for treating metastatic cases that have failed prior endocrine therapies.

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the grant of stock options to two new employees, totaling 11,800 shares, effective April 3, 2023. The options, part of the 2022 Inducement Plan, vest over four years, with 25% on the first anniversary and the remainder monthly for three years. The exercise price is set at $3.49, reflecting the last reported stock price. This move underscores Olema's commitment to attracting talent as it develops targeted therapies for women’s cancers, particularly the lead candidate, OP-1250, which is in Phase 2 trials for ER-positive breast cancer.

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) reported significant progress in its lead program, OP-1250, with over 170 patients treated. The company is set to initiate its first pivotal Phase 3 trial of OP-1250 for metastatic breast cancer in the latter half of 2023. Financially, Olema held $204.4 million in cash as of December 31, 2022, sufficient to fund operations through 2025. However, the company reported a net loss of $26.2 million for Q4 and $104.8 million for the full year, driven by increased R&D spending. Organizational restructuring will reduce the workforce by 25% to focus on OP-1250’s late-stage development.

Olema Pharmaceuticals (Nasdaq: OLMA) announced the grant of stock options to three new employees totaling 42,300 shares effective March 1, 2023. These stock options, approved by the Compensation Committee, are part of the 2022 Inducement Plan and vest over four years, with an exercise price of $4.01 per share. Olema is a clinical-stage biopharmaceutical company focused on targeted therapies for women’s cancers, notably their lead candidate OP-1250, which is under evaluation for ER+/HER2- breast cancer and has received FDA Fast Track designation.

Olema Pharmaceuticals, Nasdaq: OLMA, announced that CEO Sean Bohen will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 2:40 p.m. ET. A live webcast of this event will be accessible on Olema's investor relations website, and it will remain archived for 30 days. Olema focuses on developing targeted therapies for women's cancers, with its lead candidate OP-1250, an oral small molecule, currently in a Phase 2 trial for ER+/HER2- breast cancer. OP-1250 has received FDA Fast Track designation for patients who have not responded to prior endocrine therapy.

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, is set to present at two investor conferences. Sean Bohen, M.D., will engage in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 12:00 p.m. ET. Additionally, Shane Kovacs will participate in the Breast and Lung Cancer Corporate Panel at Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. A live webcast of these events will be available on Olema’s Investor Relations website and archived for 30 days. Olema's lead candidate, OP-1250, is an FDA Fast Track designated drug for ER-positive breast cancer.